A report by the General Accounting Office concludes that current patent law discourages drug companies from developing new drugs by allowing them to make excessive profits through minor changes to existing pharmaceuticals. Pharma R&D spending has increased 147% since ‘93, but applications for “new molecular entity” drugs, have only increased 7%

read more | digg story